Risk impact of edoxaban in the management of stroke and venous thromboembolism

References

• MillerCSGrandiSMShimonyAMeta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillationAm J Cardiol2012110345346022537354
   PubMed Web of Science ®Google Scholar
• RuffCTGiuglianoRPBraunwaldEComparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsLancet2014383992195596224315724
   PubMed Web of Science ®Google Scholar
• WilkeTGrothAMuellerSOral anticoagulation use by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patientsThromb Haemost201210761053106522398417
   PubMed Web of Science ®Google Scholar
• SchneeweissSGagneJJPatrickARComparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillationCirc Cardiovasc Qual Outcomes20125448048622787066
   PubMed Web of Science ®Google Scholar
• YehCHGrossPLWeitzJIEvolving use of new oral anticoagulants for treatment of venous thromboembolismBlood201412471020102824923298
   PubMed Web of Science ®Google Scholar
• EastonJDLopesRDBahitMCApixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trialLancet Neurol201211650351122572202
   PubMed Web of Science ®Google Scholar
• HalvorsenSAtarDYangHEfficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trialEur Heart J201435281864187224561548
   PubMed Web of Science ®Google Scholar
• LopesRDAlexanderJHAl-KhatibSMApixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationaleAm Heart J2010159333133920211292
   PubMed Web of Science ®Google Scholar
• HalperinJLHankeyGJWojdylaDMEfficacy and safety of rivaroxaban compared with warfarin among elderly patients with non-valvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)Circulation2014130213814624895454
   PubMed Web of Science ®Google Scholar
• HartRGDienerHCYangSIntracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trialStroke20124361511151722492518
   PubMed Web of Science ®Google Scholar
• OldgrenJAlingsMDariusHRisks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trialAnn Intern Med201115510660667W20422084332
   PubMed Web of Science ®Google Scholar
• CammAJLipGYDe CaterinaR2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation–developed with the special contribution of the European Heart Rhythm AssociationEuropace201214101385141322923145
   PubMed Web of Science ®Google Scholar
• JanuaryCTWannLSAlpertJS2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm SocietyJ Am Coll Cardiol20146421e17624685669
   PubMed Web of Science ®Google Scholar
• KearonCAklEAComerotaAJAntithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesChest20121412 Supple419S94S22315268
   PubMed Web of Science ®Google Scholar
• KurodaYHirayamaCHotodaHPostmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgeryVasc Health Risk Manag2013959359824124376
   PubMedGoogle Scholar
• RuffCTGiuglianoRPBraunwaldEAssociation between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trialLancet201538599842288229525769361
   PubMed Web of Science ®Google Scholar
• SaidKHokusai-VTE: Edoxaban for the treatment of venous thromboembolismGlob Cardiol Sci Pract20132013441642024749116
   PubMedGoogle Scholar
• OgataKMendell-HararyJTachibanaMClinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteersJ Clin Pharmacol201050774375320081065
   PubMed Web of Science ®Google Scholar
• WeitzJIConnollySJPatelIRandomised, parallel-group, multi-centre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillationThromb Haemost2010104363364120694273
   PubMed Web of Science ®Google Scholar
• BathalaMSMasumotoHOgumaTPharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humansDrug Metab Dispos201240122250225522936313
   PubMed Web of Science ®Google Scholar
• RuffCTGiuglianoRPAntmanEMEvaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48)Am Heart J2010160463564120934556
   PubMed Web of Science ®Google Scholar
• GoASHylekEMPhillipsKAPrevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) StudyJAMA2001285182370237511343485
   PubMed Web of Science ®Google Scholar
• LipGYNieuwlaatRPistersRRefining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillationChest2010137226327219762550
   PubMed Web of Science ®Google Scholar
• ChungNJeonHKLienLMSafety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillationThromb Haemost2011105353554421136011
   PubMed Web of Science ®Google Scholar
• YamashitaTKoretsuneYYasakaMRandomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillationCirc J20127681840184722664798
   PubMed Web of Science ®Google Scholar
• HoganHHealeyFNealeGPreventable deaths due to problems in care in English acute hospitals: a retrospective case record review studyBMJ Qual Saf2012219737745
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical ExcellenceNICE cost impact and commissioning assessment: quality standard for VTE prevention Available from: https://www.nice.org.uk/guidance/qs3/resources/cost-impact-and-commissioning-assessment-quality-standard-for-venous-thromboembolism-vte-prevention-252274141Accessed May 5, 2016
   Google Scholar
• National Institute for Health and Clinical ExcellenceVenous thromboembolism: reducing the risk for patients in hospital Available from: https://www.nice.org.uk/guidance/cg92Accessed May 5, 2016
   Google Scholar
• FujiTWangCJFujitaSSafety and efficacy of edoxaban, an oral factor Xa inhibitor, versus enoxaparin for thromboprophylaxis after total knee arthroplasty: the STARS E-3 trialThromb Res201413461198120425294589
   PubMed Web of Science ®Google Scholar
• FujiTFujitaSKawaiYEfficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-VThromb J2015132726269694
   PubMed Web of Science ®Google Scholar
• RobertsonLKestevenPMcCaslinJEOral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of deep vein thrombosisCochrane Database Syst Rev20156CD01095626123214
   PubMedGoogle Scholar
• FujiTFujitaSKawaiYSafety and efficacy of edoxaban in patients undergoing hip fracture surgeryThromb Res201413361016102224680549
   PubMed Web of Science ®Google Scholar
• ChristerssonCWallentinLAnderssonUD-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation–observations from the ARISTOTLE trialJ Thromb Haemost20141291401141224942912
   PubMed Web of Science ®Google Scholar
• HylekEMHeldCAlexanderJHMajor bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical OutcomesJ Am Coll Cardiol201463202141214724657685
   PubMed Web of Science ®Google Scholar
• KeelingDCotterFManagement of bleeding in patients taking FXa and FIIa inhibitorsBr J Haematol201316011223110431
   PubMed Web of Science ®Google Scholar
• ShakurHRobertsIBautistaREffects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trialLancet20103769734233220554319
   PubMed Web of Science ®Google Scholar
• NakamuraMWangYQWangCEfficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trialJ Thromb Haemost20151391606161426179767
   PubMed Web of Science ®Google Scholar
• CaldeiraDCostaJFerreiraJJNon-vitamin K antagonist oral anti-coagulants in the cardioversion of patients with atrial fibrillation: systematic review and meta-analysisClin Res Cardiol2015104758259025643952
   PubMed Web of Science ®Google Scholar
• LoffredoLPerriLDel BenMNew oral anticoagulants for the treatment of acute venous thromboembolism: are they safer than vitamin K antagonists? A meta-analysis of the interventional trialsIntern Emerg Med201510449950625539954
   PubMed Web of Science ®Google Scholar
• SardarPChatterjeeSLavieCJRisk of major bleeding in different indications for new oral anticoagulants: insights from a meta-analysis of approved dosages from 50 randomized trialsInt J Cardiol201517927928725464465
   PubMed Web of Science ®Google Scholar